t(4;14), and revised myeloma comorbidity index as good predictors of survival for multiple myeloma.

IF 2.3 4区医学 Q2 HEMATOLOGY

Expert Review of Hematology Pub Date : 2025-07-14 DOI:10.1080/17474086.2025.2534706

Aline G Ramirez-Alvarado, Susana Gabriela Gonzalez-Prieto, Yael Solis-Aranda, Ana Paulina Rivera-Espinoza, Jaime Garcia-Chavez, Laura Arcelia Montiel-Cervantes, Jorge Vela-Ojeda

{"title":"t(4;14), and revised myeloma comorbidity index as good predictors of survival for multiple myeloma.","authors":"Aline G Ramirez-Alvarado, Susana Gabriela Gonzalez-Prieto, Yael Solis-Aranda, Ana Paulina Rivera-Espinoza, Jaime Garcia-Chavez, Laura Arcelia Montiel-Cervantes, Jorge Vela-Ojeda","doi":"10.1080/17474086.2025.2534706","DOIUrl":null,"url":null,"abstract":"Background: Cytogenetic tests are essential prognostic indicators for patients diagnosed with multiple myeloma (MM). The study aimed to evaluate the prevalence of cytogenetic abnormalities and their prognostic significance in patients with newly diagnosed MM.Research design and methods: A cohort study involving 88 cases. Malignant plasma cells were isolated, and interphase fluorescent in situ hybridization was performed on bone marrow samples.Results: The gain of 1q was observed in 17 (19%) patients, followed by t(4;14) in 10 (11.5%), and the 17p or P53 mutation was found in only 6 (7%) patients. Three patients (3.5%) exhibited t(14;16). Amplification of 1q was not detected in any of the samples. The presence of t(4;14), anemia, renal disease, a revised myeloma comorbidity index (R-MCI) of 7-9, and a lack of treatment response were associated with poor progression-free survival. Additionally, t(4;14), anemia, elevated LDH, an R-MCI of 7-9, and absence of maintenance treatment correlated with decreased overall survival. In the Cox regression analysis, the presence of t(4;14) and an R-MCI of 7-9 were the most significant factors predicting worse outcomes.Conclusions: The t(4;14) and RMCI are reliable predictors of poor survival in newly diagnosed MM patients.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-8"},"PeriodicalIF":2.3000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2025.2534706","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cytogenetic tests are essential prognostic indicators for patients diagnosed with multiple myeloma (MM). The study aimed to evaluate the prevalence of cytogenetic abnormalities and their prognostic significance in patients with newly diagnosed MM.

Research design and methods: A cohort study involving 88 cases. Malignant plasma cells were isolated, and interphase fluorescent in situ hybridization was performed on bone marrow samples.

Results: The gain of 1q was observed in 17 (19%) patients, followed by t(4;14) in 10 (11.5%), and the 17p or P53 mutation was found in only 6 (7%) patients. Three patients (3.5%) exhibited t(14;16). Amplification of 1q was not detected in any of the samples. The presence of t(4;14), anemia, renal disease, a revised myeloma comorbidity index (R-MCI) of 7-9, and a lack of treatment response were associated with poor progression-free survival. Additionally, t(4;14), anemia, elevated LDH, an R-MCI of 7-9, and absence of maintenance treatment correlated with decreased overall survival. In the Cox regression analysis, the presence of t(4;14) and an R-MCI of 7-9 were the most significant factors predicting worse outcomes.

Conclusions: The t(4;14) and RMCI are reliable predictors of poor survival in newly diagnosed MM patients.

查看原文本刊更多论文

T（4;14）和修订后的骨髓瘤合并症指数作为多发性骨髓瘤生存的良好预测指标。

背景：细胞遗传学检查是诊断多发性骨髓瘤（MM）患者的基本预后指标。本研究旨在评估新诊断mm患者细胞遗传学异常的患病率及其预后意义。研究设计和方法：88例队列研究。分离恶性浆细胞，对骨髓标本进行间期荧光原位杂交。结果：17例（19%）患者出现1q增加，10例（11.5%）患者出现t（4;14）增加，仅6例（7%）患者出现17p或P53突变。3例（3.5%）出现t（14;16）。在所有样品中均未检测到1q的扩增。t（4;14）、贫血、肾脏疾病、修订后的骨髓瘤合并症指数（R-MCI）为7-9，以及缺乏治疗反应与无进展生存期差相关。此外，t（4;14）、贫血、LDH升高、R-MCI为7-9以及缺乏维持治疗与总生存期降低相关。在Cox回归分析中，t（4;14）和R-MCI为7-9是预测预后较差的最显著因素。结论：t（4;14）和RMCI是新诊断MM患者生存不良的可靠预测因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Hematology HEMATOLOGY-

CiteScore

4.70

自引率

3.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.